A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Amit M OzaUrsula A MatulonisAngeles Alvarez SecordJohn NemunaitisLynda D RomanSarah P BlagdenSusana BanerjeeWilliam P McGuireSharad GhamandeMichael J BirrerGini F FlemingMerry-Jennifer MarkhamHal W HirteDiane M ProvencherBristi BasuRebecca KristeleitDeborah K ArmstrongBenjamin SchwartzPatricia BralyGeoff D HallKenneth P NephewSimone JueligerAram OganesianSue NaimYong HaoHarold KeerMohammad AzabDaniela MateiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Although this trial did not show superiority for PFS of G+C versus TC, the 6-month PFS increased in G+C treated patients. Further refinement of this strategy should focus on identification of predictive markers for patient selection.